These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 20938098

  • 1. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Hahn JY, Song YB, Choi JH, Choi SH, Lee SY, Park HS, Hur SH, Lee S, Han KR, Rha SW, Cho BR, Park JS, Yoon J, Lim DS, Lee SH, Gwon HC, DATE Registry Investigators.
    Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R, CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators.
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [Abstract] [Full Text] [Related]

  • 3. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X, Chen F, He J, Gao Y, Wu C, Luo Y, Zhang X, Zhang Y, Ren X, Lv S.
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [Abstract] [Full Text] [Related]

  • 6. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela EL, Perin MA, Devito FS, Labrunie A, Salvadori D, Gusmão M, Staico R, Costa JR, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators.
    JAMA; 2013 Dec 18; 310(23):2510-22. PubMed ID: 24177257
    [Abstract] [Full Text] [Related]

  • 7. Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry.
    Sgueglia GA, Burzotta F, Trani C, Todaro D, Talarico GP, Niccoli G, Porto I, Leone AM, Coluccia V, Mazzari MA, Mongiardo R, Schiavoni G, Crea F.
    Catheter Cardiovasc Interv; 2011 Mar 01; 77(4):503-9. PubMed ID: 20602477
    [Abstract] [Full Text] [Related]

  • 8. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S.
    Circ Cardiovasc Interv; 2012 Jun 01; 5(3):372-80. PubMed ID: 22668555
    [Abstract] [Full Text] [Related]

  • 9. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S, De Luca G, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F, MATRIX Study Investigators.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):408-16. PubMed ID: 21735531
    [Abstract] [Full Text] [Related]

  • 10. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.
    Chen KY, Rha SW, Wang L, Li YJ, Li GP, Poddar KL, Park JY, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ, KAMIR Investigators.
    JACC Cardiovasc Interv; 2012 Sep 01; 5(9):936-45. PubMed ID: 22995881
    [Abstract] [Full Text] [Related]

  • 11. Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
    Sangiorgi GM, Morice MC, Bramucci E, Ferlini M, Grinfeld L, Petronio AS, Pierli C, Iadanza A, Biondi-Zoccai G, Colombo A.
    EuroIntervention; 2011 Nov 01; 7(7):813-9. PubMed ID: 22082577
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ.
    JACC Cardiovasc Interv; 2008 Oct 01; 1(5):494-503. PubMed ID: 19463351
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB.
    JACC Cardiovasc Interv; 2011 May 01; 4(5):543-50. PubMed ID: 21596327
    [Abstract] [Full Text] [Related]

  • 16. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
    Lee BK, Kim JS, Lee OH, Min PK, Yoon YW, Hong BK, Shin DH, Kang TS, Kim BO, Cho DK, Jeon DW, Woo SI, Choi S, Kim YH, Kang WC, Kim S, Kim BK, Hong MK, Jang Y, Kwon HM.
    EuroIntervention; 2018 Mar 20; 13(16):1923-1930. PubMed ID: 29104179
    [Abstract] [Full Text] [Related]

  • 17. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, van Geuns RJ, van Es GA, Kalesan B, Wenaweser P, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2011 Aug 20; 4(8):887-95. PubMed ID: 21851904
    [Abstract] [Full Text] [Related]

  • 18. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    Han YL, Zhang L, Yang LX, Liu HL, Qu P, Li WM, Jiang TM, Li SM, Jing QM, Zhang QY, Xu B, Li Y, Gao RL.
    EuroIntervention; 2012 Nov 22; 8(7):815-22. PubMed ID: 23171802
    [Abstract] [Full Text] [Related]

  • 19. Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
    Steinwender C, Hartenthaler B, Lambert T, Kypta A, Kammler J, Hönig S, Hofmann R, Kerschner K, Leisch F.
    EuroIntervention; 2009 Mar 22; 4(5):593-9. PubMed ID: 19378679
    [Abstract] [Full Text] [Related]

  • 20. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD, Kirtane AJ, Brodie BR, Witzenbichler B, Litherland C, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Gurbel PA, Mehran R, Généreux P, Ben-Yehuda O, Simonton CA, Stone GW, ADAPT-DES Investigators.
    JACC Cardiovasc Interv; 2017 Aug 28; 10(16):1607-1617. PubMed ID: 28780034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.